Immunovant
(NASDAQ) IMVT
Immunovant Financials at a Glance
Market Cap
$4.81B
Revenue (TTM)
$0.00
Net Income (TTM)
$464.20M
EPS (TTM)
$-2.68
P/E Ratio
-8.82
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$22.97
Volume
40,736
Open
$23.67
Price
$22.97
Volume
40,736
Open
$23.67
Previous Close
$22.97
Daily Range
$22.81 - $24.00
52-Week Range
$12.72 - $29.25
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$22.97
Volume
40,736
Open
$23.67
Previous Close
$22.97
Daily Range
$22.81 - $24.00
52-Week Range
$12.72 - $29.25
IMVT News
IMVT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Immunovant
Industry
Biotechnology
Sector
Health CareEmployees
362
CEO
Eric Venker, MD, PharmD
Website
www.immunovant.comHeadquarters
New York City, NY 10018, US
IMVT Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-69%
Return on Capital
-49%
Return on Assets
-44%
Earnings Yield
-11.34%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$4.81B
Shares Outstanding
203.53M
Volume
40.74K
Short Interest
0.00%
Avg. Volume
1.33M
Financials (TTM)
Gross Profit
$0.00
Operating Income
$438.15M
EBITDA
$437.77M
Operating Cash Flow
$375.87M
Capital Expenditure
$759.00K
Free Cash Flow
$376.63M
Cash & ST Invst.
$713.97M
Total Debt
$98.00K
Immunovant Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$101.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$4.81B
N/A
Market Cap/Employee
$13.30M
N/A
Employees
362
N/A
Net Income
$110.64M
+0.4%
EBITDA
$108.98M
+4.6%
Quarterly Fundamentals
Net Cash
$994.52M
+165.4%
Accounts Receivable
$1.64M
-26.1%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
-100.0%
Return on Assets
-44.11%
N/A
Return on Invested Capital
-49.40%
N/A
Free Cash Flow
$92.33M
+8.2%
Operating Cash Flow
$92.33M
+8.0%